Diabetic Neuropathy Market Trends

  • Report ID: 4526
  • Published Date: Jul 29, 2024
  • Report Format: PDF, PPT

Diabetic Neuropathy Market Trends

Growth Drivers

  • Rising Improper Diet in People with Increasing Preference for Outdoor Food and Disposable Income – Consuming unhealthy foods such as sugary drinks, processed and fried foods leads to weight gain, obesity, and the development of chronic diseases. Also, eating an unhealthy diet leads to disorders including cardiovascular diseases, cancer, communicable and non-communicable diseases, and infections. All these elements are estimated to boost market growth. As per the data collected, obesity affected over 750 million adults across the world in 2020
  • Rising Population Rates with Increasing Living Standards and Longevity – Increasing population is expected to increase the incidence of diabetic cases among the people, and it is expected to drive the market’s growth in the upcoming year. As per the reported data, the world population increased to 7.8 billion in 2021 up from 7.3 billion in 2015.
  • Increasing Practice of a Sedentary Lifestyle that Leads to Weight Gain Issues - Approximately 3.2 million deaths and 32.1 million DALYs (representing about 2.1% of global DALYs) each year are caused by insufficient physical activity.
  • Rising Awareness Regarding Diagnosis and Treatment Among People – It was observed that 1.5 million new diabetic cases were diagnosed in 2018 in the U.S.

Challenges

  • High Cost of Treatment for Neuropathic Pain - The market's future is being hampered by the rising cost of the medications used to treat diabetic neuropathy market. The availability of alternate treatments, such as radiotherapy and physiotherapy, appears to be more convenient and results in better clinical outcomes for the patients. As per recent data, pharmacological therapy expenses each year and over the course are considered USD 13.80 for expert consultations and USD 10.50 for general practitioners.
  • Undiagnosed Cases of Diabetes
  • Lack of Access to People for Proper Medical Care

Diabetic Neuropathy Market: Key Insights

Base Year

2023

Forecast Year

2024-2036

CAGR

8.5%

Base Year Market Size (2023)

USD 5.43 Billion

Forecast Year Market Size (2036)

USD 15.67 Billion

Regional Scope

  • North America (U.S., and Canada)
  • Latin America (Mexico, Argentina, Rest of Latin America)
  • Asia-Pacific (Japan, China, India, Indonesia, Malaysia, Australia, Rest of Asia-Pacific)
  • Europe (U.K., Germany, France, Italy, Spain, Russia, NORDIC, Rest of Europe)
  • Middle East and Africa (Israel, GCC North Africa, South Africa, Rest of the Middle East and Africa)
Get more information on this report: Request Free Sample PDF

Browse Key Market Insights with Data Illustration:


Author Credits:  Radhika Pawar


  • Report ID: 4526
  • Published Date: Jul 29, 2024
  • Report Format: PDF, PPT

Frequently Asked Questions (FAQ)

In the year 2024, the industry size of diabetic neuropathy is estimated at USD 5.85 Billion.

The diabetic neuropathy market size was valued at USD 5.43 Billion in 2023 and is poised to cross USD 15.67 Billion by the end of 2036, registering more than 8.5% CAGR during the forecast period i.e., between 2024-2036. Increasing cases of diabetes and a rising population are major factors driving the market growth.

North America industry is predicted to dominate largest revenue share by 2036, due to rising prevalence of diabetes along with increasing geriatric population, and the growing healthcare expenditure on diabetes in the region.

Hoffmann-La Roche Ltd., Abbott Laboratories, Eli Lilly and Company, Johnson & Johnson Services, Inc., GlaxoSmithKline plc, Lupin Limited, Glenmark Pharmaceuticals Limited, Assertio Holdings, Inc., Astellas Pharma US, Inc., Pfizer Inc.
Inquiry Before Buying Request Free Sample
logo
  GET A FREE SAMPLE

FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.

 Request Free Sample Copy

Have questions before ordering this report?

Inquiry Before Buying